Today’s Watch List : GlycoMimetics, Inc. (NASDAQ:GLYC), Altria Group Inc. (NYSE:MO), Science Applications International Corporation (NYSE:SAIC), Karyopharm Therapeutics, Inc. (NASDAQ:KPTI), Selectica (NASDAQ:SLTC)

GlycoMimetics, Inc. (NASDAQ:GLYC) announced that CEO Rachel King will provide a company presentation at the 13th Annual BIO Investor Forum on Tuesday, October 7, 2014 at 1:30 p.m. Eastern Time. GlycoMimetics, Inc. (NASDAQ:GLYC) belongs to Healthcare sector. Its net profit margin is -73.70% and weekly performance is 0.83%. On last trading day company shares ended up $7.25. GlycoMimetics, Inc. (NASDAQ:GLYC) distance from 50-day simple moving average (SMA50) is -7.81%.

Altria Group (NYSE:MO) has earned a “BBB” credit rating from analysts at Morningstar. The investment research firm’s “BBB” rating suggests that the company is a moderate default risk. They also gave their stock a two star rating. Altria Group Inc. (NYSE:MO) shares advanced 1.58% in last trading session and ended the day at $46.19. MO Gross Margin is 41.30% and its return on assets is 12.40%. Altria Group Inc. (NYSE:MO) quarterly performance is 9.69%.

Science Applications International Corp (NASDAQ:SAIC) Insider Douglas Martin Wagoner sold 6,902 shares of Science Applications International Corp stock on the open market in a transaction dated Wednesday, September 17th. The stock was sold at an average price of $46.21, for a total transaction of $318,941.42. Following the sale, the insider now directly owns 50,418 shares of the company’s stock, valued at approximately $2,329,816. On 03 October, Science Applications International Corporation (NYSE:SAIC) shares advanced 2.04% and was closed at $46.53. SAIC EPS growth in last 5 year was 0.00%. Science Applications International Corporation (NYSE:SAIC) year to date (YTD) performance is 43.74%.

On Sept. 29, Karyopharm Therapeutics, Inc. (NASDAQ:KPTI), announced the presentation of clinical data from an ongoing Phase 1 clinical study for its lead product candidate, Selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE™ compound, in patients with advanced solid tumors. Data presented in patients with chemotherapy refractory, castrate-resistant prostate cancer (CRPC) treated with single-agent Selinexor showed a 60% disease control rate with maximum prostate-specific antigen (PSA) reduction ranging from 27% to 60% and duration of treatment up to 502 days. Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) ended the last trading day at $33.09. Company weekly volatility is calculated as 8.65% and price to cash ratio as 8.17. Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) showed a weekly performance of -21.40%.

On Sep 30, Selectica, Inc. (NASDAQ:SLTC) introduced configurable contract approval workflows for Iasta SmartSource Contract Management. Automating contract approval processes are proven to demonstrate: Reduced contract-cycle time ; Contract and supplier risk avoidance; Enhanced employee productivity; Detailed audit trail and Identification of inefficiencies in approval processes. Selectica, Inc. (NASDAQ:SLTC) shares moved down -5.84% in last trading session and ended the day at $5.64. SLTC Gross Margin is 42.10% and its return on assets is -65.60%. Selectica, Inc. (NASDAQ:SLTC) quarterly performance is -14.67%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone